Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

ConditionsBreast Cancer Anthracycline Related Cardiotoxicity in Breast Cancer Virtual Reality Trastuzumab

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexFemale

Age18+

SponsorVirginia Commonwealth University

About this trial

The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Additionally, follow-up assessments will examine changes in women's cancer therapy related cardiac dysfunction knowledge and heart healthy behaviors (e.g., physical activity).

Eligibility criteria

Qualifiers

18 years of age or older

Able to speak and read in English

Actively receiving Trastuzumab or an anthracycline-based treatment

Currently receiving immunotherapy. This includes pembrolizumab and atezolizumab.

Disqualifiers

None

Trial design

Treatments tested in this trial

Cardiovascular Health Education and Gaming through Virtual Reality

Treatment groups

30 Participants

are divided into 1 treatment group

Sponsors and collaborators

Virginia Commonwealth University

Lead sponsor

Source ClinicalTrials.gov